Effects of subjective symptoms and quality of life by the adherence with anti-histamine ophthalmic solution in patients with seasonal allergic conjunctivitis - A multicenter, prospective, cross-sectional study
Not Applicable
- Conditions
- seasonal allergic conjunctivitis
- Registration Number
- JPRN-UMIN000039554
- Lead Sponsor
- Santen Pharmaceutical Co., Ltd.
- Brief Summary
The improvement of the overall QOL scale score in the proactive use group after propensity score matching was significantly greater than that in the as-needed use group (P??=??0.002). The twice-daily eye formulations significantly improved QOL in "outdoor activities" and "social life" compared to the four-times-daily formulations, (Allergy no Rinsyo [Allergy Pract]. 2021;41(8):37-46)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 418
Inclusion Criteria
Not provided
Exclusion Criteria
Patient with severe allergic conjunctival disease (VKC, atopic keratoconjunctivitis) Patient who received treatment before pollen dispersal for seasonal allergic conjunctivitis after the end of 2019
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Effect of subjective symptoms and QOL with ophthalmic solutions adherence status
- Secondary Outcome Measures
Name Time Method